COVID-19 Exacerbates Challenges For ATMP Developers In The EU
The Number Of Advanced Therapy Products On The Market Remains Low
The COVID-19 pandemic has added to the many hurdles companies face when it comes to developing and marketing advanced therapy medicinal products in the EU. Jackie Mulryne of law firm Arnold & Porter suggests some factors they should consider when planning their EU market strategy for ATMPs.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.